prescriptify
GLP-1 · POM · Prescribed in the UK

Weight, finally answered.

Mounjaro and Wegovy are the most studied, most effective weight-loss medications ever brought to market. We dispense both, prescribed by our UK pharmacists, titrated weekly, delivered in chilled couture packaging. The category was always going to grow up. We decided to be the pharmacy that grew up first.

20.9%
AVG WEIGHT REDUCTION (SURMOUNT-1, 72 WKS)
94%
PATIENT ADHERENCE AT 12 WEEKS (INTERNAL)
24h
PRESCRIBER REVIEW WINDOW

Prescription-only medicine. Treatment is only available following an online consultation with one of our prescribing pharmacists.

TIRZEPATIDE · POM · GLP-1 + GIP DUAL AGONIST

Mounjaro

A dual agonist that targets both GLP-1 and GIP receptors, reducing appetite and improving glycaemic control. The single most effective weight-loss medicine currently available in the UK on prescription.

DOSINGWeekly subcutaneous injection
TITRATION2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
DURATION12–18 months supervised
FROM£199 / month
SEMAGLUTIDE · POM · GLP-1 AGONIST

Wegovy

The original GLP-1 weight-loss medicine. Once-weekly semaglutide, titrated over four months to the maintenance dose of 2.4mg. Extensive safety data; widely tolerated.

DOSINGWeekly subcutaneous injection
TITRATION0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
DURATION12–18 months supervised
FROM£179 / month

What's actually happening in your body.

GLP-1 RECEPTOR BINDING
01.

Slows gastric emptying

Meals satiate for longer.

02.

Reduces appetite signalling

The food noise quiets.

03.

Improves insulin sensitivity

Your metabolism resets.

04.

Sustained over months

The body recalibrates a new set point.

Your 12-month protocol

A medicine like this deserves a programme, not a transaction.

MONTH 1

Initiation

We start at the lowest dose. Most side effects (mild nausea, fatigue) appear here and resolve within two weeks. Your pharmacist checks in on day 7 and day 21.

01 / 04
MONTH 2–3

Titration

Dose increases stepwise. We don't escalate if your body isn't ready. The aim is comfortable, not fast.

02 / 04
MONTH 4–9

Active phase

You're on your maintenance dose. Most patients see steady, sustained loss of 0.5–1% body weight per week. We're tracking metabolic markers, not just the scale.

03 / 04
MONTH 10–12

Stabilisation

We taper or maintain depending on goal and biomarkers. The research is clear: this works best as a long-term, supervised therapy, not a crash diet in pen form.

04 / 04

Honesty about who this is for.

You may be eligible if
  • You're over 18 and a UK resident.
  • Your BMI is over 30, or over 27 with a weight-related condition.
  • You've considered or attempted lifestyle change first.
  • You're not pregnant, breastfeeding, or planning pregnancy soon.
  • You're prepared to take this seriously: weekly injections, monthly pharmacist reviews, real engagement with your health.
We will decline if
  • You have a personal or family history of medullary thyroid cancer or MEN2.
  • You have severe gastrointestinal disease, pancreatitis history, or active eating disorder.
  • You're under 18 or considered clinically inappropriate after review.
  • You're seeking a quick aesthetic fix rather than a metabolic intervention.

This list is not exhaustive. Your pharmacist's review covers a fuller picture, including your medication history, family history, and any contraindications relevant to your case. We refuse approximately 18% of applications.

What no other UK telehealth site will tell you in plain English.

LIKELY · MORE THAN 1 IN 10
  • Mild to moderate nausea, especially in the first 2 weeks.
  • Fatigue, reduced energy during titration.
  • Constipation or, less often, diarrhoea.
  • Mild headache.
POSSIBLE · 1 IN 10 TO 1 IN 100
  • Dizziness, dehydration if fluids not increased.
  • Reflux, burping, gastrointestinal discomfort.
  • Injection-site irritation.
SERIOUS · RARE, CALL US IMMEDIATELY
  • Severe abdominal pain (possible pancreatitis).
  • Unusual visual changes (rare retinal effects).
  • Severe vomiting or signs of dehydration.
24/7 PHARMACIST LINE

If something feels wrong, we answer.

Transparent, monthly, no auto-trap.

STARTER

Wegovy initiation

£179/ month

Suitable for most starting patients.

Dose, pen, dispatch, pharmacist supervision, secure messaging.
MOST PRESCRIBED
STANDARD

Mounjaro maintenance

£249/ month

The most commonly prescribed regime once titrated.

Everything above + biomarker review at month 6.
EXTENDED

Mounjaro 12.5mg / 15mg

£329/ month

Higher-dose maintenance for those clinically titrated up.

Everything above + quarterly metabolic panel.

Pause or cancel anytime. No fee. We never auto-renew without your active consent.

How we differ from the rest of the market.

StandardTypical UK telehealthPrescriptify
Owns its dispensaryOften outsourcedYes, in-house
Pharmacist namedAnonymousNamed, registered
Prescribing reviewAlgorithm + sign-offFull pharmacist read
Cold chain monitoredVariable2–8°C end-to-end
Auto-renewal trapCommonNo auto-renewal
Refusal rateRarely disclosed18% of applications
Side-effect supportEmail queue24/7 pharmacist line

We chose to compete on standards, not on price. We think you'll feel the difference at the unboxing.

Weight-loss, honestly answered.

In SURMOUNT-1, the average tirzepatide patient lost 20.9% of body weight over 72 weeks. We won't promise that for you, averages are averages. What we will promise is that the medicine, the supervision, and the protocol you're getting are the same standard used in the trial.

Ready to be assessed?

It takes about 6 minutes. You'll choose your treatment and pay at the end. If our pharmacist cannot approve you, the full amount is refunded automatically within minutes.